X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs VENUS REMEDIES - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER VENUS REMEDIES PFIZER/
VENUS REMEDIES
 
P/E (TTM) x 30.9 -688.2 - View Chart
P/BV x 4.9 0.2 2,437.6% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 PFIZER   VENUS REMEDIES
EQUITY SHARE DATA
    PFIZER
Mar-16
VENUS REMEDIES
Mar-16
PFIZER/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs2,724218 1,249.5%   
Low Rs1,61182 1,962.2%   
Sales per share (Unadj.) Rs440.9365.6 120.6%  
Earnings per share (Unadj.) Rs48.71.5 3,276.8%  
Cash flow per share (Unadj.) Rs75.837.9 199.8%  
Dividends per share (Unadj.) Rs15.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs462.9382.5 121.0%  
Shares outstanding (eoy) m45.7511.44 399.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.90.4 1,197.9%   
Avg P/E ratio x44.5101.0 44.1%  
P/CF ratio (eoy) x28.64.0 722.9%  
Price / Book Value ratio x4.70.4 1,193.6%  
Dividend payout %30.80-   
Avg Mkt Cap Rs m99,1631,717 5,776.8%   
No. of employees `0002.91.0 283.2%   
Total wages/salary Rs m2,758324 850.0%   
Avg. sales/employee Rs Th6,981.74,100.7 170.3%   
Avg. wages/employee Rs Th954.5318.0 300.1%   
Avg. net profit/employee Rs Th771.116.7 4,626.7%   
INCOME DATA
Net Sales Rs m20,1704,183 482.2%  
Other income Rs m85720 4,265.7%   
Total revenues Rs m21,0284,203 500.3%   
Gross profit Rs m4,310812 531.0%  
Depreciation Rs m1,239417 297.2%   
Interest Rs m5380 1.4%   
Profit before tax Rs m3,92335 11,177.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,79418 9,913.8%   
Profit after tax Rs m2,22817 13,104.5%  
Gross profit margin %21.419.4 110.1%  
Effective tax rate %45.751.6 88.7%   
Net profit margin %11.00.4 2,717.5%  
BALANCE SHEET DATA
Current assets Rs m16,2992,771 588.2%   
Current liabilities Rs m7,5941,931 393.2%   
Net working cap to sales %43.220.1 215.1%  
Current ratio x2.11.4 149.6%  
Inventory Days Days65125 52.2%  
Debtors Days Days2654 47.9%  
Net fixed assets Rs m8,6225,328 161.8%   
Share capital Rs m458114 399.9%   
"Free" reserves Rs m20,7224,177 496.1%   
Net worth Rs m21,1804,376 484.0%   
Long term debt Rs m251,911 1.3%   
Total assets Rs m29,1378,428 345.7%  
Interest coverage x755.51.1 69,156.8%   
Debt to equity ratio x00.4 0.3%  
Sales to assets ratio x0.70.5 139.5%   
Return on assets %7.74.7 162.8%  
Return on equity %10.50.4 2,707.7%  
Return on capital %19.06.6 287.8%  
Exports to sales %0.10-   
Imports to sales %17.520.5 85.2%   
Exports (fob) Rs m12NA-   
Imports (cif) Rs m3,526858 410.8%   
Fx inflow Rs m520-   
Fx outflow Rs m140858 16.3%   
Net fx Rs m-88-858 10.3%   
CASH FLOW
From Operations Rs m3,436469 733.0%  
From Investments Rs m-6,99129 -23,941.4%  
From Financial Activity Rs m-619-464 133.5%  
Net Cashflow Rs m-4,17435 -12,097.1%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 0.2 4,166.7%  
FIIs % 4.9 0.6 844.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 66.4 35.7%  
Shareholders   85,207 20,121 423.5%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 22, 2018 09:27 AM

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS